The Strange Untold Story of How Science Solved Narcolepsy: A Closer Look

This news article details the fascinating journey of scientific discovery that led to solving the mystery of narcolepsy. Here’s a breakdown of the key points:

The Players:

• Masashi Yanagisawa: A Japanese scientist who discovered orexin (hypocretin) while researching G-protein-coupled receptors.
• J. Gregor Sutcliffe: Led the team that discovered hypocretin at the Scripps Research Institute.
• Thomas Kilduff: Joined Sutcliffe’s lab and later worked on canine narcolepsy research.
• Richard Chemelli: Yanagisawa’s student who discovered the narcolepsy-like symptoms in orexin-knockout mice.
• Thomas Scammell: A Harvard neurologist who investigated the effects of modafinil on orexin neurons.
• William Dement: Pioneered sleep medicine and established a canine narcolepsy colony at Stanford.
• Emmanuel Mignot: A French pharmacologist who studied narcolepsy in dogs and later human brains.
• Jerome Siegel: A UCLA professor who investigated the cause of narcolepsy in human brains.

The Discoveries:

• 1996: Yanagisawa discovers orexin while studying G-protein-coupled receptors.
• 1998 (Early January): Sutcliffe’s team discovers hypocretin and its role in stimulating neurons.
• 1998 (February): Yanagisawa publishes his findings on orexin, unaware of the simultaneous discovery.
• 1998: Chemelli observes narcolepsy-like symptoms in orexin-knockout mice.
• Late 1990s: Mignot identifies a mutation in the hypocretin-2 receptor gene as the cause of narcolepsy in dogs.
• 1999 (August 6): Mignot’s paper on canine narcolepsy is published in Cell.
• 1999 (Two weeks later): Yanagisawa’s paper on orexin and narcolepsy is published in Cell.
• 2000: Siegel discovers a massive loss of hypocretin neurons in human narcoleptic brains.
• 2000 (Late August): Mignot and Siegel realize the overlap in their human narcolepsy research.
• 2000 (September): Mignot’s paper on the lack of hypocretin in human narcolepsy is published.
• 2018: Siegel’s team discovers significantly more hypocretin neurons in the brains of heroin addicts.
• 2022: Siegel’s team shows morphine alters hypocretin neuron pathways in mice and that removing these neurons eliminates opioid withdrawal symptoms.

The Impact:

• These discoveries led to a simple diagnostic test for narcolepsy by measuring hypocretin levels.
• The development of hypocretin replacement therapy is ongoing.
• Medications targeting the hypocretin system may offer new treatments for opioid addiction.

Interesting Points:

• The near-simultaneous discovery of orexin/hypocretin by two independent teams highlights the phenomenon of “multiple discovery” in science.
• Competition and collaboration played a role in the research process.
• The discovery of hypocretin’s link to pleasure-seeking behavior was unexpected.
• The potential application of hypocretin research in treating opioid addiction is a significant development.

Overall, this article showcases the dedication and collaboration of scientists in unraveling the mysteries of the brain and developing new treatments for complex disorders.